-
Some issues are a result of still being paper driven as timely reports and real time information are not available, but they are not the only government agency in this scenario, only one of the most critical though. Also, some members of Congress don’t use computers either and felt uncomfortable...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-26-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Medical Records, Pharma, FDA, Congress, integration, CMS, Leavitt
-
New abbreviation here to become acquainted with (PGx) which is pharmacogenics, and one more move in the direction of personalized medicine by big Pharma as the marketing of blockbuster drugs slowly evolves to a new business model with genomic data input becoming a part of the process to bring new drugs...
-
It is here but evolving slower than what all of us might like to see, and in many areas it is still so much of a “Science” but as developments occur through biotech we are seeing some amazing results. There’s also the bridging of the gap with bringing genomics to the point of care, as physicians...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-26-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Pharma, Biotech, Cancer, tumors, Genentech, Herceptin, cancer vaccine
-
Recently announced is the project to begin at Scripps in San Diego as related news, coupled with the announcement of the new sequencing service that will be able to offer a complete sequence at a wholesale price may have held a bit of inspiration here for Navigenics to enter the full sequencing market...
-
However, their prescription drug unit faced the same problems as the rest of the Pharma industry. A smart investment in consumer products is helping hold things together for J and J. The consumer product division was purchased from Pfizer in 2006, which was the company purchased by Pfizer...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-14-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, personalized medicine, Genomics, Pharma, Pfizer, Phamaceuticals, Consumer Goods, J and J, Warner Lambert
-
As the article states, you don’t need marketing for cancer drugs, as the need is unfortunately already there, thus marketing for cancer drugs does not necessarily carry the same sales expense as do other drugs. We have all seen the “tiered plans” on what level drugs are listed with insurance coverage...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-13-2008
Filed under:
Filed under: Medically Related, Insurance, Other Items of Interest, My Commentaries, personalized medicine, Genomics, health insurance, Pharma, Prescriptions, Cancer, R and D, Science 2.0
-
Not only do we see venture capital money here, also some big Pharma names. In a related story, Roche sees diagnostic machines and test kits as crucial to assessing and treating disease in the future and their risk profile has recognition of being one large investor in a growing area of drug research...
-
Three companies teaming together to create a DNA based test to determine which patients will benefit from selected drug treatments. The one for breast cancer is already available, so one more effort towards more information from the start and smarter clinical trials. BD NEW YORK (GenomeWeb...
-
Genomics is back on the list for Congress, with creating an additional new agency and a focus on collecting the necessary information to allow research and development. Also included would be guidelines and rules related to genetic and pharmacogenomic tests to bring both Pharma and medical...
-
Interesting correlation on how the move business and Pharma share similar business plans when it comes to producing a blockbuster drug. R and D, yup, got high costs with both, unpredictable, yup, nobody knows until the release, budgets and flops, well it could be a toss up over which industry can...
-
One CEO comes out and states how biotech will be the new focus for Glaxo, as in a related story whereby patients will require genetic testing for their AIDS drug, Ziagen. In the future I’m sure there will be more about big pharma and their biotech strategies as personalized medicine continues...
-
More business action with big pharma and the biotech industry, although Roche and Genentech already are invested together and have worked on conjunction on research projects. Roche acquired a majority in Genentech in 1990 and currently owns 55.9% of all outstanding shares. Roche...
-
The recent turn of events has literally put the FDA on somewhat of a hot seat... for an agency that minimally invested in technology, compared to other government entities, it is finding itself in a position of having to play "catch up" in a hurry...as evidenced with the recent turn of events...
-
Interesting article and makes sense as personalized medicine moves in...there could be a rise for the need of local owned pharmacies unless the large chains refocus to accommodate the consumer needs...BD In pharmacies, everything old might be new again, particularly for the independent, locally owned...